Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage
Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo
Tesamorelin is studied as a GHRH analog with relevance to pituitary-axis signaling, GH release models, IGF-1 pathway activity, and metabolic regulation
Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress
In trials, tirzepatide showed it could help people lose up to 22.5% of their total body weight
Migraine Currently, there is not a comprehensive theory or hypothesis explaining all phenomena associated with migraines
